Örebro University Hospital
- Address
- Universitetssjukhuset Örebro, Department of Internal Medicine, Södra Grev Rosengatan, 70185 Örebro, Sweden
Hematology – Neoplasms
The Hematology department at Örebro University Hospital concentrates on blood‑related cancers, aiming to improve treatment outcomes for patients with newly diagnosed conditions.
- MRD‑guided treatment strategies
- Combination therapies with venetoclax
- Clinical evaluation of novel agents
With four investigators leading two active trials, the site contributes valuable data to European oncology research.
Chronic Lymphocytic Leukemia & Small Lymphocytic Lymphoma
Research targets previously untreated CLL and SLL, comparing personalized treatment durations based on measurable residual disease to fixed‑cycle regimens.
- Venetoclax plus pirtobrutinib
- Venetoclax plus obinutuzumab
- Progression‑free survival assessment
The goal is to refine therapy length, enhancing patient quality of life while maintaining effectiveness.
Higher‑Risk Myelodysplastic Syndrome
Studies evaluate new drug combinations for adults with high‑risk MDS, seeking to boost response rates compared with standard azacitidine therapy.
- Lisaftoclax plus azacitidine
- Placebo-controlled comparison
- Overall survival and transfusion independence
By testing innovative agents, the site aims to expand therapeutic options for this challenging bone‑marrow disorder.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 5 of 6 therapeutic areas and 14 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 4 by active trials.
- 1Ascentage Pharma Group Inc.1active
lock +3 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 188 other sites in Sweden
Therapeutic Area Benchmark — Sweden
Select a therapeutic area to compare against other sites in Sweden.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Sweden
Market Share
Country: Sweden
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Örebro University Hospital
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Study of Acalabrutinib and Venetoclax in Newly Diagnosed Chronic Lymphocytic Leukemia Patients at High Risk of Infection or Early Treatment | Region Hovedstaden | Phase II | Not Recruiting | Jun 2024 | — |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Venetoclax | 2 | Unknown | 2024-06-12 | 2025-06-12 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.